These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2987601)

  • 1. [Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies].
    Wander HE; Blossey HC; Nagel GA; Emrich D
    Klin Wochenschr; 1985 Apr; 63(7):312-8. PubMed ID: 2987601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.
    Willemse PH; van der Ploeg E; Sleijfer DT; Tjabbes T; van Veelen H
    Eur J Cancer; 1990 Mar; 26(3):337-43. PubMed ID: 2141491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.
    Lundgren S; Lønning PE; Aakvaag A; Kvinnsland S
    Cancer Chemother Pharmacol; 1990; 27(2):101-5. PubMed ID: 2249324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral high-dose progestins as treatment for advanced breast cancer.
    Lundgren S; Kvinnsland S; Utaaker E
    Acta Oncol; 1989; 28(6):811-6. PubMed ID: 2532917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.
    Alexieva-Figusch J; Blankenstein MA; Hop WC; Klijn JG; Lamberts SW; de Jong FH; Docter R; Adlercreutz H; van Gilse HA
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):33-40. PubMed ID: 6363095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer.
    Alexieva-Figusch J; Blankenstein MA; de Jong FH; Lamberts SW
    Eur J Cancer Clin Oncol; 1984 Sep; 20(9):135-40. PubMed ID: 6434315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Megestrol acetate therapy and secondary adrenal suppression.
    Naing KK; Dewar JA; Leese GP
    Cancer; 1999 Sep; 86(6):1044-9. PubMed ID: 10491532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal steroids as parameters of the bioavailability of MA and MPA.
    Willemse PH; Dikkeschei LD; Tjabbes T; van Veelen H; Sleijfer DT
    Eur J Cancer; 1990 Mar; 26(3):359-62. PubMed ID: 2141494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose megestrol acetate in the treatment of advanced breast cancer.
    Tchekmedyian NS; Tait N; Abrams J; Aisner J
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):44-9. PubMed ID: 3368800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer.
    Miller AA; Becher R; Schmidt CG
    J Cancer Res Clin Oncol; 1988; 114(2):186-90. PubMed ID: 2965155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study).
    Alexieva-Figusch J; Van Putten WL; van Gilse HA; Blonk-vd Wijst J; Klijn JG
    Med Oncol Tumor Pharmacother; 1985; 2(2):69-75. PubMed ID: 4058078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Megestrol acetate: a new role in the treatment of metastatic breast cancer.
    Allegra JC
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):45-7. PubMed ID: 3589707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings.
    Lundgren S; Lønning PE; Utaaker E; Aakvaag A; Kvinnsland S
    J Steroid Biochem; 1990 Jun; 36(1-2):99-104. PubMed ID: 2362454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment.
    Blackledge GR; Latief T; Mould JJ; Spooner D; Morrison M
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1091-4. PubMed ID: 2946584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose progestin therapy for metastatic breast cancer.
    Muss HB; Cruz JM
    Ann Oncol; 1992 Aug; 3 Suppl 3():15-20. PubMed ID: 1390312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progestational agents in advanced breast cancer: an overview.
    Haller DG; Glick JH
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):2-8. PubMed ID: 3026051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate.
    Blossey HC; Wander HE; Koebberling J; Nagel GA
    Cancer; 1984 Sep; 54(6 Suppl):1208-15. PubMed ID: 6088020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose megestrol acetate as third-line endocrine therapy for metastatic breast cancer.
    Cruz JM; Muss HB; Russell G
    Oncology; 1992; 49 Suppl 2():8-11. PubMed ID: 1461630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles].
    Wander HE; Blossey C; Köbberling J; Nagel GA
    Klin Wochenschr; 1983 Jun; 61(11):553-60. PubMed ID: 6224046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
    Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
    J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.